bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
PATHADD05

Order Name:
Immunohistochemical stain: Ki-67

 
Useful For:
A marker of proliferation in neoplasms
 
Methodology:
Immunohistochemistry
 
 
 
Test Code:
PATHADD05

Order Name:
Immunohistochemical stain: Ki-67

 
Collection Specimen Or Container:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 2 slides
 
Specimen Testing Type:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 2 slides
 
Sub Mission Container:
1. Tissue in 10% neutral buffered formalin or 
2. Paraffin embedded tissue block or
3. Unstained positively charged slides as least 2 slides
 
Rejection Criteria:
1. Wet/ frozen tissue Cytology smears 
2. Non formalin fixed tissue 
3. Non paraffin embedded tissue 
4. Non charged slides
 
Specimen Stabillity:
 
Specimen Type Temperature
Tissue 1. Room temperature for Tissue in 10% neutral buffered formalin
2. Room temperature for paraffin embedded tissue block and unstained slide
(Breast tissue should be fixed in formalin for 6-48 hours, not to exceed 72 hours )
 
 
 
Test Code:
PATHADD05

Order Name:
Immunohistochemical stain: Ki-67

 
Method detail:
Immunohistochemistry
 
Schedule:
Tested daily, at 07:00 am. - 06:00 pm.
 
Turnaround Time:
5-7 days
 
Performing Location:
Surgical Pathology, Laboratory Department Tel.14146
 
Specimen Retention Time:
10 years after final report
 
 
 
Test Code:
PATHADD05

Order Name:
Immunohistochemical stain: Ki-67

 
 
Clinical Information:
Ki-67 (antibody clone MIB-1), is a nuclear protein playing a pivotal role in maintaining cell proliferation. Ki-67 is present in all non-G0 phases of the cell cycle. Beginning in the mid-G1, the level increases through S and G2 to reach a peak in M phase. In the end of M phase, it is rapidly catabolized. Ki-67 has been employed as a marker of proliferation and, hence, prognosis in neoplasms of many types, such as malignant lymphomas, prostatic and breast adenocarcinomas, astrocytic neoplasms, and soft tissue neoplasms.
 
Clinical Reference:
https://www.mayocliniclabs.com (Retrieved: 29 Jan 2019)